

FIGURE 1




FIGURE 2





FIGURE 3

														•																•					
			1	: :	ř		1	2		¥	数		1	\$		1	*		1	蒙		1	27		1	2		\$	æ		\$. 2			
per a	KD9	٠.			-	- ~	*** ***				2	•			*** *			٠.	•		¥	4900	-					THE REAL PROPERTY.						C	oronavirus
120.7	***************************************	` -	ń		**	?h		Eta	(19)		. 3	SHAKE			minus			······			still me			softer.			4245			-9750				8	pike Protein
KI SI	HBA)	-						19			ŧ	·úa ·									-		•			•									
				98 200	311 255							•																							
43 32.0		樂	7	•		,			:			125						415:11-			*1891			3.			**************************************			up.					
																											•								
. 12.8	***************************************														,																				
*	4			4				_																											•
	descians.	5	Kiriin:	na m	eisup	ŀ	2060	Ŧ	ŧ	200	*	į	rea	3	ı	AGG	详		RMO	3		FRO	36		FREE	13*		Pasc	is:		Fa	säg			
																																		-	
			•																																
									•																										1 -
																											•								
				边			£				2		J	#					•				•												
			•	**		٠	-			• •	*		1	44			3	2		3	. #r	-	7	2		7	12	٠ ٩	4	2	1	, ;	2		
\$20, \$140 t																									~ ** 714				***					4-	. Coronavirus
120.7	Attendant.	~g			111.12			1Hir	G-			Time.			4	ei H			12/1/24						CHAN			******			dinte		•	•	Spike Protei
manisa		:						***				-du			1214	31			mat .						A. 16.			. 1,							
		* *	in the state of	MATE.																Atten					本有能 有									-\$ -	Coronavirus
45X 337-33				•	Ŗń			-11	•			514			孄	ð			រក់ដ្ឋាភិព្						SEPPE SAME			. W.			This.				nudeoprotei
			•		•										12				al,									omes,							
17.5												,			*****	1.			•						Wit.			m sm			į · ·				
r Anisto	ode: lane	retr	n Sá	tan.	p		iro		100	GG1	9		Face	ron-		**	20G:			F26	rou ao		Face	.		muan						mose.	arte.		
- 415.60			****				~ ,			arratil 1	~			E 133		#1	KIP (A)	od.		ET ACRES	a. B		1"2000	# 13.7		Pæs	KI C	. 14	2EG	115	ŧ	FEGG	154		
-			•							•							•					٠.	•												

1 Purified Virus

2 Infected Cell lysale

FIGURE 4






FIGURE 5




FIGURE 6A

SARS CoV mAb V_H alignment




FIGURE 6 B

SARS-specific monoclonal antibodies, Heavy chains (VH), amino acid sequences

F26G3-VH

EVRLQQSGPELVKPGASVKISCKTSGYTFTEYTMHWVKQSHGKNLEWIGGINPNNGGTTYNQKFKG KATLTVDKSSNTAYMELRSLTSEDSAVYYCSRGDYGTSYGYFDVWGAGTTVTVSSAKTTAPSVYPL A

F26G7-VH

VELLESGTVLARPGASVKMSCEASGYTFTTYWMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKGK AKLTAVTSTSTAYMELSSLTNEDSAVYYCTREGIPQLLRTMDYWGQGTSVTVSSAKTTPPSV

F26G9-VH

VQLLESGTVLARPGASVKMSCKASGYSFT SYWMHWVKQRPGQGLEWIGAIYPGNSDTSYNQKFKGK AKLTAVTSASTAYMELSSLTNEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTPPSV

F26G10-VH

EVQLEESGTVLARPGASVKMSCKASGYSFTSYWMHWVKQRPGQGLDWIGAIYPENSDTSYNQKFKG KAKLTAVTSASTAYMEHSSLTNEDSAVYYCTRSVYYGYGYFDVWGAGTTVTVSSAKTTAPSVYPLA PVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQ SITCNVAHPASSTKVDKKIEPRVPTSQN

F26G18-VH

LVQLEESGTVLPRPGASVKMSCKASGYTFTSYWMHWVKQRPGQGLEWIGAIYPGNSDTNYNQKFKG RATLTAVTSTSTASMELSSLTNEDSAVYYCTRDGYGSLYYYAMDFWGQGTSVTVSSAKTTAPSVK

F26G19-VH

EVQLEESGTVLARPGASVKMSCKASGYTFTTYRMHWIKQRPGQGLEWIGAIYPGNSDTTYNQKFKD KAKLTAVTSTSSAYMELSSLTNEDSAVYFCTREGIPQLLRTLDYWGQGTSVTVSSAKTTAPSVYPL A

F26G1-VH

EVQLEESGPGLVAPSQSLSITCTVSGFSLTNYDISWIRQPPGKGLEWLGIIWTGGGTSYNSAFMSR LSISKDNSKSQVFLKMNSLQTDDTAIYYCVRDRVYYFPMDYWGQGTSVTVSSAKTTAPSVYPLA

F26G6-VH

MEWSWVFLFLVATATDVHSQVQLQQPGAELVKPGASVKVSCKASGYTFTNYWIHWVKQRPGQGLEW IGEINPGNGRTNYNGNFMNKATLTVDKSSNTAYMQLSSLTSEDSAVYHCARLDYWGQGTTLTVSSA KTTPPSV

F26G8-VH

VQLLESGAELVKPGASVKVSCKASGYTFTSYWIHWVKQRPGQGLEWIGEINPSNGRTNYNGNFESK ATLTVDKSSNTAYMHLSSLTYEDSAVYHCTRLDYWGQGTTLTVSSAKTTAPSVYPLA

Neutralizing mAbs are in bold text.

FIGURE 7

SARS-specific monoclonal antibodies, Light chains (VL), amino acid sequences

F26G3-VL

DILMTQSPTSFAVSLGQRATISCRTSQSVSTSSYSYMHWYQQKPGQPPKLLIKYASNLESGVPARF SGSGSGSDFTLNIHPVEEGDTATYYCQHSWEIPCAFGGGTKLEIKRADAAPTVS

F26G7-VL

ELVMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSGVPKRFSGSR SGSDYSLTISSLESEDFADYYCLQYISYPWTFGGGTKLEIKRADAAPTVS

F26G9-VL

DILMTQSHKCMSTSVGDRVSITCKASQDVSTAVVWYQQKPGQFPKLLIYWASTRHTGVPDRFTGSG SGTDYTLTISSVQAEDLALYYCQQHYTTPYTFGGGTKLEIKRADAAPTVS

F26G10-VL

DILMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSG SGTDYTLTISSVQAEDLALYYCQQHYSTPYTFGGGTKLEIKRADAAPTVS

F26G18-VL

ELVMTQSPSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTSRLHAGVPSRFSGSG SGTDYSLTISNLEQEDIATYFCQQGYTLPYTFGGGTKLEIKRADAAPTVSKGEFQHTGGRY

F26G19-VL

DILMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQEKPDGTIKRLIYAASTLDSGVPKRFSGSR SGSDYSLTISSLESEDFADYYCLOYVSYPWTFGGGTKLEIKRADAAPTV

F26G1-VI.

 $\verb|ELVMTQSPVSITASRGEKVTITCRASSSISSNYLHWYQQKPGSSPKLLIYRTSILASGVLDTFSGS|\\ GSESSYTLTISCMQDEVAATYYCQQGSSSPPHVRRGDQAGNKTG|\\$

F26G6-VL

 ${\tt ELVMTQSPASLSVATGKKVTIRCISSTDIDDDMNWYQQKAGKPPKLLISEGNIFSPGVPSRFSSG} \\ {\tt NGTDFVFTVENTLSEDVADNYCLQSDNMPFTFGSGTKLGIKRADAAPTVS}$

F26G8-VL

ELVMTQSPASLSVITGKKVTIRCISNTDIDDDLNWSQLKAGEPPKLLISEGNIFSPGVPSRFSSSG NGTDFVFTIENTLSEDVANNYCFOSDNMPFTFGSGTKLEIKRADAAPTVS

Neutralizing mAbs are in **bold text**.

FIGURE 8

SARS-specific monoclonal antibodies, Heavy chains (VH), nucleotide sequences

F26G3-VH

F26G7-VH

F26G9-VH

F26G10-VH

F26G18-VH

FIGURE 9-1

F26G19-VH

F26G1-VH

F26G6-VH

F26G8-VH

Neutralizing mAbs are in bold text.

FIGURE 9-2

SARS-specific monoclonal antibodies, Light chains (VL), nucleotide sequences

F26G3-VL

F26G7-VL

GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCATCCTCCTTATCTGCCTCTCTGGGAGAAAGAG TCAGTCTCACTTGTCGGGCAAGTCAGGAAATTAGTGGTTATTTAAGCTGGCTTCAGCAGAAACCAG ATGGAACTATTAAACGCCTGATCTACGCCGCATCCACTTTAGATTCGGGTGTCCCAAAAAGGTTCA GTGGCAGTAGGTCTGGGTCAGATTATTCTCTCACCATCAGCAGCCTTGAGTCTGAAGATTTTGCAG ACTATTACTGTCTACAATATATTAGTTATCCGTGGACGTTCGGGGGGAGGTACCAAGCTGGAAATCA AACGGGCTGATGCTGCACCAACTGTATCC

F26G9-VL

GACATTCTGATGACCCAGTCTCACAAATGCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACC
TGCAAGGCCAGTCAGGATGTGAGTACTGCTGTAGTCTGGTATCAACAAAAACCAGGGCAATTTCCT
AAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTTGGA
TCTGGGACAGATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCACTTTATTACTGT
CAGCAACATTATACCACTCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAACGGGCTGAT
GCTGCACCAACTGTATCC

F26G10-VL

GGGCCCAGCCGAGCTCGACATTCTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAG
GAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAAC
AAAAACCAGGGCAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTG
ATCGCTTCACAGGCAGTGGATCTGGGACAGATTATACTCTCACCATCAGCAGTGTGCAGGCTGAAG
ACCTGGCACTTTATTACTGTCAGCAACATTATAGCACTCCGTACACGTTCGGAGGGGGGGACCAAGC
TGGAAATAAAACGGGCTGATGCTGCACCAACTGTATCC

F26G18-VL

F26G19-VL

FIGURE 10-1

F26G1-VL

F26G6-VL


GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGGCTACAGGAAAAAAAG
TCACCATCAGATGCATAAGCAGCACTGACATTGATGATGATATGAACTGGTACCAGCAGAAGGCAG
GAAAACCTCCTAAACTCCTTATTTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCT
CCAGCAGTGGCAATGGCACAGATTTTGTTTTTACAGTTGAAAACACGCTCTCAGAAGATGTTGCAG
ATAACTACTGTTTGCAAAGTGATAACATGCCATTCACGTTCGGCTCGGGGACAAAGTTGGGAATAA
AACGGGCTGATGCTGCACCAACTGTATCC

F26G8-VL


GTGCCAGATGTGAGCTCGTGATGACCCAGTCTCCAGCATCCCTGTCCGTGATTACAGGAAAAAAAG
TCACCATCAGATGCATAAGCAACACTGACATTGATGATGATTTGAACTGGTCCCAGCTGAAGGCAG
GAGAACCTCCTAAACTCCTTATTTCAGAAGGCAATATTTTTAGTCCTGGAGTCCCATCCCGATTCT
CCAGCAGTGGCAATGGCACAGATTTTGTTTTTACAATTGAAAACACGCTCTCAGAAGATGTTGCAA
ATAACTACTGTTTCCAAAGTGATAACATGCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAA
AACGGGCTGATGCTGCACCAACTGTATCC

Neutralizing mAbs are in **bold text**.


FIGURE 10-2



(A)




(B)



(C)

FIGURE 11






Figure 12

(B)




Figure 13